Scientists hunt for clues to personalize lung cancer treatment
NCT ID NCT04312308
Summary
This study aimed to find biological markers in the blood and tumors of lung cancer patients that could predict who would benefit from the immunotherapy drug atezolizumab. It involved 100 patients with advanced non-small cell lung cancer whose disease had progressed after prior treatment. The research focused on analyzing immune cells, genetics, and gut bacteria to understand treatment response, not on testing a new cure.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yonsei Severance Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.